BioWorld

Nov. 12, 2004

View Archived Issues

OSI Offering Garners $387M; Tarceva Waiting On Runway

With 6 million shares offered at $64.50 each, OSI Pharmaceuticals Inc. is raising $387 million while waiting with partner Genentech Inc. for word from the FDA regarding Tarceva, their drug for non-small-cell lung cancer. (BioWorld Today) Read More

Zephyr Getting Neuprex In Potential $73M XOMA Deal

Read More

Geron Raises $40M Privately To Fund Oncology Products

Read More

Inspire Pharmaceuticals Gets $37.6M In Sale Of Public Stock

Read More

Other News To Note

Read More

Appointments And Advancements

Read More